Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.
暂无分享,去创建一个
D. Heron | R. Seethala | Lin Wang | J. Grandis | S. Dacic | R. Ferris | Seungwon Kim | A. Argiris | D. Posluszny | B. Branstetter | S. Lai | M. Gibson | W. Gooding | Jonas T. Johnson | Ryan P. Smith
[1] G. Calais,et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Heron,et al. Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] W. Gahl,et al. Audiologic and Otologic Manifestations of Hutchinson‐Gilford Progeria Syndrome , 2010 .
[4] W. Westra,et al. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus‐associated head and neck cancer based on a prospective clinical experience , 2010, Cancer.
[5] S. Dacic,et al. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas , 2010, Modern Pathology.
[6] R. Ferris,et al. Novel Immunogenic HLA-A*0201-restricted Epidermal Growth Factor Receptor-specific T-cell Epitope in Head and Neck Cancer Patients , 2010, Journal of immunotherapy.
[7] D. Heron,et al. Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: The University of Pittsburgh experience , 2009, The Laryngoscope.
[8] R. Tishler,et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] G. Calais,et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. , 2009, Journal of the National Cancer Institute.
[10] J. Pignon,et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[11] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[12] J. Moon,et al. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216) , 2009, Head & neck.
[13] J. García-Saenz,et al. A single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Chung,et al. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Bokemeyer,et al. Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Grandis,et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells , 2009, Cancer Immunology, Immunotherapy.
[17] R. Kurzrock,et al. The role of investigational therapy in management of patients with advanced metastatic malignancy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] C. Bokemeyer,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.
[19] M. Karamouzis,et al. Head and neck cancer , 2008, The Lancet.
[20] R. Ferris,et al. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. , 2007, Archives of otolaryngology--head & neck surgery.
[21] T. Gorlia,et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. , 2007, The New England journal of medicine.
[22] A. Markoe,et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. , 2007, The New England journal of medicine.
[23] M. Karamouzis,et al. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. , 2007, JAMA.
[24] S. Spencer,et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303) , 2007 .
[25] Christine H Chung,et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[27] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[28] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[29] E. Vokes,et al. The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy‐head and neck scale: A study of utility and validity , 1996, Cancer.
[30] A. Garden,et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] L. Tanoue. Cancer Statistics, 2009 , 2010 .
[32] G. Calais,et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.